The Physicians Committee for Responsible Medicine, a nonprofit that advocates for nonanimal science, is applauding the new ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory ...